-
, histone modifications, and non-coding RNAs. Exploring the genetics of early-onset and familial/hereditary colorectal cancers. Studying the tumor microenvironment, stem cells, immune regulation, and
-
malignancies using engineered cellular therapies. We are looking for a highly motivated candidate with a PhD and/or MD degree interested in combining novel rational and combinatorial synthetic biology approaches
-
the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature Cancer (2024), Blood (2022, 2019, 2019), Blood Cancer Journal (2022), Cell Stem
-
below: · https://www.ncbi.nlm.nih.gov/myncbi/1ZUMm9-Cb59Al/bibliography/public/ · Nature Cancer (2023), Blood (2022, 2019, 2019), Blood Cancer Journal (2022), Cell Stem Cell (2018). As a
-
, including first-in-human studies with genetically engineered hematopoietic stem and progenitor cells (HSPC) and T cells. As a successful candidate, you will: · Conduct research on next-generation
-
colorectal cancers. Studying the tumor microenvironment, stem cells, immune regulation, and identifying targeted therapies. Investigating extracellular vesicles/exosomes in cancer pathogenesis and as disease
-
, histone modifications and non-coding RNAs. 3) The genetic basis of early-onset and familial/hereditary colorectal cancers. 4) The role of tumor microenvironment, stem cells, immune regulation and